Facilities

Phase 1 Capability

Phase 1 population

∼2 million over geographically large region

Mechanisms studied

Taxanes, TKI inhibitors, CDK inhibitors, aurora kinase inhibitors, TRAIL receptor antibodies, novel cytotoxic agents, novel packaging of existing agents

First-in-Man studies

Yes

Centre specific translational research interest

DNA repair inhibitors, pre-clinical and early clinical development of small molecule inhibitors

Multi-centre Phase 1 studies

Yes

 

Technology/equipment available within the centre

  • Magnetic resonance imaging and spectroscopy (MRI/S)
  • Positron emission tomography (PET) technology
  • GCLP compliant pharmacology and pharmacodynamic assessment laboratories
 

Other Facilities (e.g. Wellcome Trust CRF)

  • Dedicated cancer research scientific institute opened 2003 (Northern Institute for Cancer Research in the Paul O'Gorman Building)
  • Dedicated academic clinical trials unit to perform early clinical work with planned move to custom built new cancer centre 2008
 

Sample collection

Tissue Banking

In house HTA-compliant tumour bank, Northern Gynaecological cancer network tumour bank, other national banks for specific projects when required.

Centre contact responsible for sample collection

Melanie Griffin (email: m.j.griffin@ncl.ac.uk)